|
|
???tair.name??? >
???browser.page.title.author???
|
"shitara k"???jsp.browse.items-by-author.description???
Showing items 1-15 of 15 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國家衛生研究院 |
2022-02 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-contr
|
Kang, YK;Chen, LT;Ryu, MH;Oh, DY;Oh, SC;Chung, HC;Lee, KW;Omori, T;Shitara, K;Sakuramoto, S;Chung, IJ;Yamaguchi, K;Kato, K;Sym, SJ;Kadowaki, S;Tsuji, K;Chen, JS;Bai, LY;Oh, SY;Choda, Y;Yasui, H;Takeuchi, K;Hirashima, Y;Hagihara, S;Boku, N |
| 國立成功大學 |
2022 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-contr
|
Kang, Y.-K.;Chen, L.-T.;Ryu, M.-H.;Oh, D.-Y.;Oh, S.C.;Chung, H.C.;Lee, K.-W.;Omori, T.;Shitara, K.;Sakuramoto, Sakuramoto S.;Chung, I.-J.;Yamaguchi, K.;Kato, Kato K.;Sym, Sym S.J.;Kadowaki, S.;Tsuji, K.;Chen, J.-S.;Bai, L.-Y.;Oh, S.-Y.;Choda, Y.;Yasui, H.;Takeuchi, K.;Hirashima, Y.;Hagihara, S.;Boku, N. |
| 國家衛生研究院 |
2021-09 |
INTEGRATE IIb: A randomised phase III open label study of regorafenib plus nivolumab vs standard chemotherapy in refractory advanced gastro-oesophageal cancer (AGOC)
|
Pavlakis, N;Shitara, K;Sjoquist, K;Martin, AJ;Jaworski, A;Yip, S;Oh, DY;Moehler, M;Chen, LT;Bekaii-Saab, T;Simes, J;Goldstein, D |
| 臺大學術典藏 |
2021-08-31T06:29:25Z |
Phase I Study of the Focal Adhesion Kinase Inhibitor BI?853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
|
Doi T.; Yang J.C.-H.; Shitara K.; Naito Y.; ANN-LII CHENG; Sarashina A.; Pronk L.C.; Takeuchi Y.; Lin C.-C. |
| 臺大學術典藏 |
2021-01-28T01:06:20Z |
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYnote-061): a randomised, open-label, controlled, phase 3 trial
|
Shitara K.;?Zg?Ro?Lu M.;Bang Y.-J.;Di Bartolomeo M.;Mandal? M.;Ryu M.-H.;Fornaro L.;Olesi?Ski T.;Caglevic C.;Chung H.C.;Muro K.;Goekkurt E.;Mansoor W.;Mcdermott R.S.;Shacham-Shmueli E.;Chen X.;Mayo C.;Kang S.P.;Ohtsu A.;Fuchs C.S.;Lerzo G.;O'Connor J.M.;Mendez G.A.;Lynam J.;Tebbutt N.;Wong M.;Strickland A.;Karapetis C.;Goldstein D.;Vasey P.;Van Laethem J.-L.;Van Cutsem E.;Berry S.;Vincent M.;Muller B.;Rey F.;Zambrano A.;Guerra J.;Krogh M.;Baeksgaard L.;Yilmaz M.;Elme A.;Magi A.;Auvinen P.;Alanko T.;Moehler M.;Kunzmann V.;Seufferlein T.;Thuss-Patience P.;Goekkurt E.;Hoehler T.;Haag G.;Al-Batran S.-E.;Castro H.;Lopez K.;Aguilar Vasquez M.;Sandoval M.;Lam K.O.;Cuffe S.;Kelly C.;Geva R.;Shacham-Shmueli E.;Hubert A.;Beny A.;Brenner B.;Giuseppe A.;Falcone A.;Maiello E.;Passalacqua R.;Montesarchio V.;Hara H.;Chin K.;Nishina T.;Komatsu Y.;Machida N.;Hironaka S.;Satoh T.;Tamura T.;Sugimoto N.;Cho H.;Omuro Y.;Kato K.;Goto M.;Hyodo I.;Yoshida K.;Baba H.;Esaki T.;Furuse J.;Wan Mohammed W.Z.;Hernandez Hernandez C.;Casas Garcia J.;Dominguez Andrade A.;Clarke K.;Hjortland G.;Glenjen N.;Kubiatowski T.;Jacek J.;Wojtukiewicz M.;Lazarev S.;Lancukhay Y.;Afanasayev S.;Moiseyenko V.;Kostorov V.;Protsenko S.;Shirinkin V.;Sakaeva D.;Fadeeva N.;Yong W.P.;Ng C.H.M.;Robertson B.;Rapaport B.;Cohen G.;Dreosti L.;Ruff P.;Jacobs C.;Landers G.;Szpak W.;Roh S.-Y.;Lee J.;Kim Y.H.;Bang Y.-J.;Chung H.C.;Ryu M.-H.;Alsina Maqueda M.;Longo Munoz F.;Cervantes Aguilar A.;Aranda Aguilar E.;Garcia Alfonso P.;Rivera F.;Feliu Batle J.;Pazo Cid R.;Kun-Huei Yeh;Chen J.-S.;Chao Y.;Yen C.-J.;?Zg?Ro?Lu M.;Kara O.;Yalcin S.;Hochhauser D.;Chau I.;Benson A.;Shankaran V.;Shaib W.;Philip P.;Sharma V.;Siegel R.;Sun W.;Wainberg Z.;George B.;Bullock A.;Myrick S.;Faruol J.;Siegel R.;Larson T.;Becerra C.;Ratnam S.;Richards D.A.;Riche S.L.;Keynote-061 Investigators; Shitara K.; ?zg?ro?lu M.; Bang Y.-J.; Di Bartolomeo M.; Mandal? M.; Ryu M.-H.; Fornaro L.; Olesi?ski T.; Caglevic C.; Chung H.C.; Muro K.; Goekkurt E.; Mansoor W.; McDermott R.S.; Shacham-Shmueli E.; Chen X.; Mayo C.; Kang S.P.; Ohtsu A.; Fuchs C.S.; Lerzo G.; O'Connor J.M.; Mendez G.A.; Lynam J.; Tebbutt N.; Wong M.; Strickland A.; Karapetis C.; Goldstein D.; Vasey P.; Van Laethem J.-L.; Van Cutsem E.; Berry S.; Vincent M.; Muller B.; Rey F.; Zambrano A.; Guerra J.; Krogh M.; Baeksgaard L.; Yilmaz M.; Elme A.; Magi A.; Auvinen P.; Alanko T.; Moehler M.; Kunzmann V.; Seufferlein T.; Thuss-Patience P.; Goekkurt E.; Hoehler T.; Haag G.; Al-Batran S.-E.; Castro H.; Lopez K.; Aguilar Vasquez M.; Sandoval M.; Lam K.O.; Cuffe S.; Kelly C.; Geva R.; Shacham-Shmueli E.; Hubert A.; Beny A.; Brenner B.; Giuseppe A.; Falcone A.; Maiello E.; Passalacqua R.; Montesarchio V.; Hara H.; Chin K.; Nishina T.; Komatsu Y.; Machida N.; Hironaka S.; Satoh T.; Tamura T.; Sugimoto N.; Cho H.; Omuro Y.; Kato K.; Goto M.; Hyodo I.; Yoshida K.; Baba H.; Esaki T.; Furuse J.; Wan Mohammed W.Z.; Hernandez Hernandez C.; Casas Garcia J.; Dominguez Andrade A.; Clarke K.; Hjortland G.; Glenjen N.; Kubiatowski T.; Jacek J.; Wojtukiewicz M.; Lazarev S.; Lancukhay Y.; Afanasayev S.; Moiseyenko V.; Kostorov V.; Protsenko S.; Shirinkin V.; Sakaeva D.; Fadeeva N.; Yong W.P.; Ng C.H.M.; Robertson B.; Rapaport B.; Cohen G.; Dreosti L.; Ruff P.; Jacobs C.; Landers G.; Szpak W.; Roh S.-Y.; Lee J.; Kim Y.H.; Bang Y.-J.; Chung H.C.; Ryu M.-H.; Alsina Maqueda M.; Longo Munoz F.; Cervantes Aguilar A.; Aranda Aguilar E.; Garcia Alfonso P.; Rivera F.; Feliu Batle J.; Pazo Cid R.; KUN-HUEI YEH; Chen J.-S.; Chao Y.; Yen C.-J.; ?zg?ro?lu M.; Kara O.; Yalcin S.; Hochhauser D.; Chau I.; Benson A.; Shankaran V.; Shaib W.; Philip P.; Sharma V.; Siegel R.; Sun W.; Wainberg Z.; George B.; Bullock A.; Myrick S.; Faruol J.; Siegel R.; Larson T.; Becerra C.; Ratnam S.; Richards D.A.; Riche S.L.; KEYnote-061 investigators |
| 臺大學術典藏 |
2021-01-28T01:06:19Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
|
Muro K.;Van Cutsem E.;Narita Y.;Pentheroudakis G.;Baba E.;Li J.;Ryu M.-H.;Wan Zamaniah W.I.;Yong W.-P.;Kun-Huei Yeh;Kato K.;Lu Z.;Cho B.C.;Nor I.M.;Ng M.;Chen L.-T.;Nakajima T.E.;Shitara K.;Kawakami H.;Tsushima T.;Yoshino T.;Lordick F.;Martinelli E.;Smyth E.C.;Arnold D.;Minami H.;Tabernero J.;Douillard J.-Y.; Muro K.; Van Cutsem E.; Narita Y.; Pentheroudakis G.; Baba E.; Li J.; Ryu M.-H.; Wan Zamaniah W.I.; Yong W.-P.; KUN-HUEI YEH; Kato K.; Lu Z.; Cho B.C.; Nor I.M.; Ng M.; Chen L.-T.; Nakajima T.E.; Shitara K.; Kawakami H.; Tsushima T.; Yoshino T.; Lordick F.; Martinelli E.; Smyth E.C.; Arnold D.; Minami H.; Tabernero J.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-01-28T01:06:18Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
|
Muro K.;Lordick F.;Tsushima T.;Pentheroudakis G.;Baba E.;Lu Z.;Cho B.C.;Nor I.M.;Ng M.;Chen L.-T.;Kato K.;Li J.;Ryu M.-H.;Wan Zamaniah W.I.;Yong W.-P.;Kun-Huei Yeh;Nakajima T.E.;Shitara K.;Kawakami H.;Narita Y.;Yoshino T.;Van Cutsem E.;Martinelli E.;Smyth E.C.;Arnold D.;Minami H.;Tabernero J.;Douillard J.-Y.; Muro K.; Lordick F.; Tsushima T.; Pentheroudakis G.; Baba E.; Lu Z.; Cho B.C.; Nor I.M.; Ng M.; Chen L.-T.; Kato K.; Li J.; Ryu M.-H.; Wan Zamaniah W.I.; Yong W.-P.; KUN-HUEI YEH; Nakajima T.E.; Shitara K.; Kawakami H.; Narita Y.; Yoshino T.; Van Cutsem E.; Martinelli E.; Smyth E.C.; Arnold D.; Minami H.; Tabernero J.; Douillard J.-Y. |
| 國立成功大學 |
2021 |
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials
|
Chao, J.;Fuchs, C.S.;Shitara, K.;Tabernero, J.;Muro, K.;Van, Cutsem E.;Bang, Y.-J.;De, Vita F.;Landers, G.;Yen, C.-J.;Chau, I.;Elme, A.;Lee, J.;Özgüroǧlu, M.;Catenacci, D.;Yoon, H.H.;Chen, E.;Adelberg, D.;Shih, C.-S.;Shah, Shah S.;Bhagia, P.;Wainberg, Z.A. |
| 國家衛生研究院 |
2020-09 |
Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
|
Boku, N;Ryu, MH;Oh, DY;Oh, SC;Chung, HC;Lee, KW;Omori, T;Shitara, K;Sakuramoto, S;Chung, IJ;Yamaguchi, K;Kato, K;Sym, SJ;Kadowaki, S;Tsuji, K;Chen, JS;Bai, LY;Chen, LT;Kang, YK |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
Phase I Study of the Focal Adhesion Kinase Inhibitor BI?853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
|
Doi T;Chih-Hsin Yang;Shitara K;Naito Y;Cheng A.-L;Sarashina A;Pronk L.C;Takeuchi Y;Lin C.-C.; Doi T; CHIH-HSIN YANG; Shitara K; Naito Y; Cheng A.-L; Sarashina A; Pronk L.C; Takeuchi Y; Lin C.-C. |
| 臺大學術典藏 |
2020-05-25T07:35:07Z |
Phase I Study of the Focal Adhesion Kinase Inhibitor BI?853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
|
Chia-Chi Lin;Takeuchi Y;Pronk L.C;Sarashina A;Cheng A.-L;Naito Y;Shitara K;Yang J.C.-H;Doi T; Doi T; Yang J.C.-H; Shitara K; Naito Y; Cheng A.-L; Sarashina A; Pronk L.C; Takeuchi Y; Chia-Chi Lin |
| 國家衛生研究院 |
2019-10 |
Randomised phase 3 study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC) - Integrate II
|
Chua, YJ;Pavlakis, N;Sjoquist, KM;Martin, AJ;Tsobanis, E;Yip, S;Bang, YJ;Alcindor, T;O'Callaghan, CJ;Bekaii-Saab, TS;Grothey, A;Chen, LT;Simes, J;Zalcberg, JR;Goldstein, D;Komatsu, Y;Machida, N;Esaki, T;Hara, H;Shitara, K |
| 國立成功大學 |
2019 |
Effect of First-line S-1 Plus Oxaliplatin with or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
|
Yoshikawa, T.;Muro, K.;Shitara, K.;Oh, D.-Y.;Kang, Y.-K.;Chung, H.C.;Kudo, T.;Chin, K.;Kadowaki, S.;Hamamoto, Y.;Hironaka, S.;Yoshida, K.;Yen, C.-J.;Omuro, Y.;Bai, L.-Y.;Maeda, K.;Ozeki, A.;Yoshikawa, R.;Kitagawa, Y. |
| 國家衛生研究院 |
2018-11-22 |
Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic gastric cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
|
Muro, K;Van Cutsem, E;Narita, Y;Pentheroudakis, G;Baba, E;Li, J;Ryu, MH;Zamaniah, WIW;Yong, WP;Yeh, KH;Kato, K;Lu, Z;Cho, BC;Nor, IM;Ng, M;Chen, LT;Nakajima, TE;Shitara, K;Kawakami, H;Tsushima, T;Yoshino, T;Lordick, F;Martinelli, E;Smyth, EC;Arnold, D;Minami, H;Tabernero, J;Douillard, JY |
| 國家衛生研究院 |
2018-11-22 |
Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic oesophageal cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
|
Muro, K;Lordick, F;Tsushima, T;Pentheroudakis, G;Baba, E;Lu, Z;Cho, BC;Nor, IM;Ng, M;Chen, LT;Kato, K;Li, J;Ryu, MH;Zamaniah, WIW;Yong, WP;Yeh, KH;Nakajima, TE;Shitara, K;Kawakami, H;Narita, Y;Yoshino, T;Van Cutsem, E;Martinelli, E;Smyth, EC;Arnold, D;Minami, H;Tabernero, J;Douillard, JY |
Showing items 1-15 of 15 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
